Literature DB >> 23713628

The association between tricuspid regurgitation velocity and 5-year survival in a North West London population of patients with sickle cell disease in the United Kingdom.

Inês Zimbarra Cabrita1, Abubakar Mohammed, Mark Layton, Sara Ghorashian, Annette Gilmore, Gavin Cho, Jo Howard, Kofi A Anie, Lynda Desforges, Paul Bassett, Julia Grapsa, Luke Howard, Gaia Mahalingam, David Dawson, Fausto J Pinto, Petros Nihoyannopoulos, Sally C Davies, J Simon R Gibbs.   

Abstract

Raised tricuspid regurgitant velocity (TRV) occurs in approximately 30% of adults with sickle cell disease (SCD), and has been shown to be an independent risk factor for death. TRV was assessed in 164 SCD patients who were subsequently followed up for survival. Raised pulmonary pressures were defined as a TRV jet ≥2.5 m/s on echocardiography. Elevated TRV was present in 29.1% of patients and it was associated with increased age and left atrial diameter. There were 15 deaths (9.1%) over a median of 68.1 months follow up; seven patients had increased TRV, and eight patients had a TRV<2.5 m/s. Higher TRV values were associated with a greater than 4-fold increased risk of death (Hazard Ratio: 4.48, 99% confidence interval 1.01-19.8), although we found a lower overall mortality rate than has been reported in previous studies. TRV was not an independent risk factor for death. We have confirmed the association between raised TRV and mortality in a UK SCD population whose disease severity appears to be less than that reported in previous studies. Further prospective studies are needed to more clearly characterize which patient factors modify survival in SCD patients with raised TRV.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  mortality; pulmonary hypertension; sickle cell disease; survival; tricuspid regurgitation velocity

Mesh:

Year:  2013        PMID: 23713628     DOI: 10.1111/bjh.12391

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  11 in total

1.  Mildly raised tricuspid regurgitant velocity 2.5-3.0 m/s in pregnant women with sickle cell disease is not associated with poor obstetric outcome - An observational cross-sectional study.

Authors:  May C Soh; Srividhya Sankaran; Natali Ya Chung; Catherine Nelson-Piercy; Jo Howard; Sue E Robinson; Eugene Oteng-Ntim
Journal:  Obstet Med       Date:  2016-08-03

Review 2.  Minireview: Clinical severity in sickle cell disease: the challenges of definition and prognostication.

Authors:  Charles T Quinn
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-23

3.  Longitudinal effect of disease-modifying therapy on tricuspid regurgitant velocity in children with sickle cell anemia.

Authors:  Parul Rai; Vijaya M Joshi; Jason F Goldberg; Amber M Yates; Victoria I Okhomina; Rhiannon Penkert; Kenneth I Ataga; Guolian Kang; Jane S Hankins
Journal:  Blood Adv       Date:  2021-01-12

Review 4.  Cardiomyopathy With Restrictive Physiology in Sickle Cell Disease.

Authors:  Omar Niss; Charles T Quinn; Adam Lane; Joshua Daily; Philip R Khoury; Nihal Bakeer; Thomas R Kimball; Jeffrey A Towbin; Punam Malik; Michael D Taylor
Journal:  JACC Cardiovasc Imaging       Date:  2016-02-17

5.  Exercise-induced changes of vital signs in adults with sickle cell disease.

Authors:  Solomon Johnson; Victor R Gordeuk; Roberto Machado; J Simon R Gibbs; Mariana Hildesheim; Jane A Little; Gregory J Kato; Mark T Gladwin; Mehdi Nouraie
Journal:  Am J Hematol       Date:  2021-10-20       Impact factor: 10.047

6.  Tricuspid regurgitation velocity and other biomarkers of mortality in children, adolescents and young adults with sickle cell disease in the United States: The PUSH study.

Authors:  Mehdi Nouraie; Deepika S Darbari; Sohail Rana; Caterina P Minniti; Oswaldo L Castro; Lori Luchtman-Jones; Craig Sable; Niti Dham; Gregory J Kato; Mark T Gladwin; Gregory Ensing; Manuel Arteta; Andrew Campbell; James G Taylor; Sergei Nekhai; Victor R Gordeuk
Journal:  Am J Hematol       Date:  2020-04-21       Impact factor: 10.047

7.  Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology.

Authors:  Nihal Bakeer; Jeanne James; Swarnava Roy; Janaka Wansapura; Shiva Kumar Shanmukhappa; John N Lorenz; Hanna Osinska; Kurt Backer; Anne-Cecile Huby; Archana Shrestha; Omar Niss; Robert Fleck; Charles T Quinn; Michael D Taylor; Enkhsaikhan Purevjav; Bruce J Aronow; Jeffrey A Towbin; Punam Malik
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-08       Impact factor: 11.205

8.  American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease.

Authors:  Robert I Liem; Sophie Lanzkron; Thomas D Coates; Laura DeCastro; Ankit A Desai; Kenneth I Ataga; Robyn T Cohen; Johnson Haynes; Ifeyinwa Osunkwo; Jeffrey D Lebensburger; James P Lash; Theodore Wun; Madeleine Verhovsek; Elodie Ontala; Rae Blaylark; Fares Alahdab; Abdulrahman Katabi; Reem A Mustafa
Journal:  Blood Adv       Date:  2019-12-10

9.  Mild Pulmonary Hypertension Is Associated With Increased Mortality: A Systematic Review and Meta-Analysis.

Authors:  Dhaval Kolte; Suvasini Lakshmanan; Matthew D Jankowich; Evan L Brittain; Bradley A Maron; Gaurav Choudhary
Journal:  J Am Heart Assoc       Date:  2018-09-18       Impact factor: 5.501

10.  Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe.

Authors:  Poulami Maitra; Melissa Caughey; Laura Robinson; Payal C Desai; Susan Jones; Mehdi Nouraie; Mark T Gladwin; Alan Hinderliter; Jianwen Cai; Kenneth I Ataga
Journal:  Haematologica       Date:  2017-01-19       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.